These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1615 related articles for article (PubMed ID: 32683540)

  • 21. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.
    Nakajima N; Kataoka M; Sugawara Y; Ochi T; Kiyoto S; Ohsumi S; Mochizuki T
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):738-46. PubMed ID: 24064322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
    Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
    J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Percentage change of primary tumor on 18F-FDG PET/CT as a prognostic factor for invasive ductal breast cancer with axillary lymph node metastasis: Comparison with MRI.
    Yoo J; Kim BS; Chung J; Yoon HJ
    Medicine (Baltimore); 2017 Aug; 96(31):e7657. PubMed ID: 28767583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 25. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 26. Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast.
    Son SH; Kim DH; Hong CM; Kim CY; Jeong SY; Lee SW; Lee J; Ahn BC
    BMC Cancer; 2014 Aug; 14():585. PubMed ID: 25112709
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Li Y; Wu X; Huang Y; Bian D; Jiang L
    Ann Nucl Med; 2020 May; 34(5):314-321. PubMed ID: 32088884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
    Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
    J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of
    Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
    Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
    [No Abstract]   [Full Text] [Related]  

  • 30. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standardized uptake value of ¹⁸F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden.
    Ahn SG; Park JT; Lee HM; Lee HW; Jeon TJ; Han K; Lee SA; Dong SM; Ryu YH; Son EJ; Jeong J
    Breast Cancer Res; 2014; 16(6):502. PubMed ID: 25551703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic parameters of [
    Markus M; Sartor H; Bjurberg M; Trägårdh E
    Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
    Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in
    Higuchi T; Fujimoto Y; Ozawa H; Bun A; Fukui R; Miyagawa Y; Imamura M; Kitajima K; Yamakado K; Miyoshi Y
    Ann Surg Oncol; 2019 Jul; 26(7):2175-2183. PubMed ID: 30941655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of
    Kitajima K; Yamano T; Miyoshi Y; Katsuura T; Enoki T; Yamakado K
    Hell J Nucl Med; 2019; 22(1):25-35. PubMed ID: 30843007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between semiquantitative and volumetric 18F-FDG PET/computed tomography parameters and Ki-67 expression in breast cancer.
    Mohamadien NRA; Sayed MHM
    Nucl Med Commun; 2021 Jun; 42(6):656-664. PubMed ID: 33560720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 81.